stem cells and materials technologies
DESCRIPTION
Stem cells and materials technologies. Group 16 - Biomaterials and waste treatment Ciência 2009, 29-30 th July 2009, Lisbon. Strategic Intent. - PowerPoint PPT PresentationTRANSCRIPT
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stem cells and materials technologiesStem cells and materials technologies
Group 16 - Biomaterials and waste treatment
Ciência 2009, 29-30th July 2009, Lisbon
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Strategic IntentStrategic Intent
To target clinical needs through the integration of advanced adult stem cell biology and novel biomaterials into
innovative therapeutic products for tissue regeneration
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
HistoryHistory
Academic spin-off of the 3B’s Research Group Created in November, 2007
Installed since September 2008 at the European Institute of Excellence for Tissue Engineering and Regenerative Medicine Research, Guimarães, Portugal.
Equipped with a future cGMP compliant facility for the processing of human tissue and cells (2003/94/EC Directive): 300 m2 of clean room (classes B, C and D);
250 m2 of R&D and QC laboratories.
1st funding round estimated to be finished by Sept, 2009 Start of operations estimated by Oct, 2009
Reception/
RegistrationRoom
Class B
Sample ProcessingRoom
Class B
Sample ProcessingRoom
Class B
Sample ProcessingRoom
Class B
Sample ExpansionRoom
Class C
Sample reception/
CentrifugationRoom
Centrifuge Room
Class D
CryopreservationRoom
Changing Room
Small Stock Room
One-way material/sample direction
Two-way material/sample direction
Personal way In through the control to the Dressing
Room
Personal way In to Class B Room
Personal way In to Class A Room
Personal way Out to the Undressing room / EXIT
Access to the cryopresevation room
Changing Clothes Passage
The material will be prepared, sterilized and packed in the “Washing room” and transfered to the near Class C pre-chamber when needed...
The workers will bring out all wastes/garbage with them to deposit at the garbage room before entering the Undressing room.All the wastes/garbage will be handled by an external company.
The workers will enter the Facilities through the “Reception Room” and according to the sample type, they will pick the necessary materials from the “Sterile Material Stock” Room and pass it to the “Material” Room near the “Dressing Room”.After changing clothes, they will enter the “Class C” corridor, if they go to one of the processing rooms or to the “Class D” corridor, if they go to the “Centrifugation Room”, taking the respective and pre-deposited material for that effect.
Dressing Room
Washing Room
Garbage
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
CSO: Rui L. Reis, CEng., MSc., PhD. (n. 1968) – Founder, President and Chief Scientific Officer: is an Associated Professor at the Department of Polymer Engineering and Director 3B’s Research Group. Editor in Chief of the Journal of Tissue Engineering and Regenerative Medicine, John Wiley and Sons Inc. He is author or co-author of more than 900 scientific publications.
CEO: Rui A. Sousa, CEng., MBA., PhD. (n. 1974) – Chief Executive Officer: is a senior researcher
at the 3B’s Research Group. Possesses business experience in several industrial and consultancy domains. He is author or co-author of more than 90 scientific publications and communications.
Dulce Costa Luísa Pereira João Oliveira Adrian Popa
TeamTeam
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Social ContextSocial Context
The WHO estimates that more than 600 million people are aged above 60, being estimated that this number reaches the 2 billion by 2050.
Growing impact of degenerative or traumatic conditions due to demographic evolution, more dynamic lifestyles, and increased physical activities.
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Regenerative Medicine
Overall MarketOverall Market
1
2
3
4
5
Adap
tado
de
Julia
n H
S G
eorg
e et
al
http:
//w
ww
.cen
trop
ede.
com
/UKS
B200
6/eP
oste
r
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Use of stem cells from adipose tissueUse of stem cells from adipose tissue
More than 1.6 billion people are overweight, of which 400 million are considered obese, with treatment costs between 2 and 8% of total health costs.
Steep increase in aesthetical surgical procedures, being Europe responsible for about one third of this global market.
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Business PortfolioBusiness Portfolio
Stemmatters Therapeutics
Stemmatters Biomedical
Stemmatters Life Banking
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters TherapeuticsStemmatters Therapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
The Market for Cartilage Regeneration
Current MarketsCurrent Markets StemmattersTherapeutics
Prevalence of articular cartilage related lesions in Europe Nearly 250.000 traumatic incidents occur; About 7 million cases of treatable arthrosis occur each year.
High market potential for cartilage regeneration Among the biggest markets for connective tissues, being estimated between 1
to 5 billion €/year in Europe alone. Very high penetration of traditional treatment approaches Arthroscopic lavage and debridement, microfracture and mosaicplasty rule the
treatment of cartilage lesions. Cell based therapies with reasonable track record in this area ACT and MACI procedures are considered market references.
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Product PipelineProduct Pipeline
ATMPs (Advanced Therapy Medicinal Products)
G01AT110C | pre-clinical | RECART Hydrogel/Adipose derived adult stem cells
G01AT300A | research | Hydrogel/Vascular stromal fraction derived cells
MDs (Medical Devices)
G01MD210B | research | Injectable filler for soft tissue applications
G01MD250B | research | Injectable filler system for maxillofacial applications
Products Under Development
StemmattersTherapeutics
Types of products currently under development:
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Product PipelineProduct Pipeline
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
Combined advanced therapy medicinal product (1394/2007 Regulation, CBMP EMEA guideline)
Polysaccharide hydrogel as an active implantable device Exopolysaccharide produced by microbial fermentation:
• Straight chain of repeating glucose, rhamnose and glucuronic acid units;
• Potential injectable system for minimally invasive surgeries;
• Processing under physiogical conditions without any reagents;
• Used in vivo for human ophthalmic applications and oral veterinary drug delivery.
Adipose derived adult stem cells Isolated from harvested adipose tissue:
• Dedicated or non-dedicated harvest procedure;
• Subpopulation isolated from the stromal vascular fraction;
• Good cell yield avoids previous cell expansion.
StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
0,001
0,01
0,1
1
10
100
1000
10000
01020304050607080
Temperature (ºC)
Vis
co
sit
y (
Pa
s)
J.T. O
livei
ra e
t al,
Pate
nt A
pplic
ation
StemmattersTherapeutics
Product PipelineProduct Pipeline
Novel hydrogel system for TE applications
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
1 WEEK 2 WEEKS 3 WEEKS
No clear macroscopic change after 3 weeks of implantation. Extremely good integration with the surrounding tissues with a residual and thin fibrotic capsule.
Good performance upon subcutaneous implantation
Product PipelineProduct Pipeline StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
col 1 col 2 aggrecan sox 90
10
20
30
40
50
60
70300
350
400
450
500
550
Nor
mal
ized
Exp
ress
ion
Rat
io
w2 w8
• Col1 was not detected after 8 weeks
Col2 increased ≈ 400 fold from 2-8 weeks
Aggrecan increased ≈ 35 fold from 2-8 weeks
Sox9 decreased close to zero from 2-8 weeks
house-keeping gene: GAPDH
8 WEEKS
Product PipelineProduct Pipeline StemmattersTherapeutics
Human chondrocytes form hyaline-like cartilage in vitro
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Product PipelineProduct Pipeline
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
ADIPOSE TISSUE FROM THE INTRASCAPULAR
REGION
ARTICULAR CARTILAGE FROM THE JOINTS
CHONDROGENIC PRE ≠ MEDIUM WITH TGF-Β1 + BMP-2
BASIC MEDIUM WITH NO PRE ≠
PROLIFERATION INDUCING MEDIUM WITH FGF-2
StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Product PipelineProduct Pipeline
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
Macroscopic observation
Histology (H&E for cell morphology and tissue formation and alcian blue for cartilage ECM formation)
Histological scoring (Pineda score)
Real-time PCR analysis (Sox9, Collagen type I, Collagen type II, and Aggrecan)
Articular cartilage full-thickness defectSubchondral drill
(Ø 1 mm)
Implantation site Rabbit articular cartilage
(4 mm x 2-3 mm thickness)
+
+
+Study groups
Autologous approach
Total implantation time: 8 weeks
[Cells]=10x106 cells/mlCharacterization
A. Gellan + adipose tissue derived cells with pre differentiation period (ASC + GF*)
B. Gellan + adipose tissue derived cells with no pre differentiation period (ASC)
C. Gellan + articular chondrocytes (AC)
D. Gellan alone (GELLAN)
E. Empty defect (EMPTY)
*TGF-Β1 + BMP-2
J.T. Oliveira et al, Patent Application
StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
Product PipelineProduct Pipeline
4 weeks4 weeks 8 weeks8 weeks0 weeks0 weeks
Patent Application/Priority date: 01.2008J.T. Oliveira et al, Patent Application
StemmattersTherapeutics
Combination of hydrogel with ASCs is able to regenerate focal cartilage lesions
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
Product PipelineProduct Pipeline StemmattersTherapeutics
0
5
10
15
20
25
30
35
40
45
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
SOX9 COL I
No
rma
lis
ed
ex
pre
ss
ion
ra
tio
165
190
215
240
265
290
315
340
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
4 WEEKS
8 WEEKSCOL II
AGGRECAN
0
5
10
15
20
25
30
35
40
45
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
SOX9 COL I
No
rma
lis
ed
ex
pre
ss
ion
ra
tio
165
190
215
240
265
290
315
340
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
AS
C +
GF
AS
C
AC
GE
LLA
N
EM
PT
Y
4 WEEKS
8 WEEKSCOL II
AGGRECAN
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Therapeutics | RECART Hydrogel/Adipose derived adult stem cells
Advantages of the cartilage repair strategy include: Potential therapeutic performance
Minimally invasive system to be administered arthroscopically
Avoids the need for a cartilage biopsy
Shorter time to therapy (TTT)
Competitive cost as compared to traditional ACT and MACI procedures
Product PipelineProduct Pipeline StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
CompetitionCompetition
Cartilage applicationArthro Kinetics, BioTissue Technologies, Cellgenix,
co.don, Curasan, Educell, Fidia Advanced Biopolymers, Geistlich Surgery, Genzyme
Biosurgery, Histogenics, Interface Biotech, Karocell Tissue Engineering, Orthogen, TIGenix,
TETEC, Verigen Transplantation Service International
Cartilage: applicationStemmatters (Autologous)
Cartilage applicationco.don, Educell, Geistlich Surgery, Genzyme
Biosurgery, Interface Biotech, TIGenix, TETEC
Cartilage applicationOsiris Therapeutics (Allogeneic)
Skin applicationOrganogenesis, BioTissue Technologies, Advanced
BioHealing, Inc., Genzyme Biosurgery, Fidia Advanced Biopolymers, Intercytex, Celltran,
Forticell Bioscience, Cambrex
Bone application Aastrom Biosciences (Autologous),
Osiris Therapeutics (Allogeneic)
Several applications:Advanced Cell Technologies, Geron, ES Cell International, Stem Cell Sciences, Aastrom Biosciences, Aldagen, Angioblast Systems,
Athersys , BrainStorm Cell Therapeutics, Cardio3, Cellerant Therapeutics, Cognate Therapeutics ,
Gamida-Cell, Mesoblast , Neuronyx, Osiris Therapeutics, AdiStem, Bioheart, Cellerix, Cognate
Therapeutics, Cytori Therapeutics , ReNeuron Group Plc, Tengion, PharmaFrontiers , Tissue
Genesis, Inc , Gamida-Cell, Saneron CCEL Therapeutics, ViaCell
Primary cellsPrimary cells Progenitor cellsProgenitor cells
Other Cell Based Therapies
Other Cell Based Therapies
Tissue Engineering Products
Tissue Engineering Products
StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Product PipelineProduct Pipeline
RECART Hydrogel/Adipose derived adult stem cells
R&D and non-clinical development
Clinical development MA Applic.
Marketing Authorization
In VivoTesting
Biomaterial R&D
In vitro testing
GMP grade
Phase I
Phase II
Phase III
2007-20102007-2010 2010-20182010-2018 20192019 20202020
Phase IV
StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Product PipelineProduct Pipeline
RECART Hydrogel/Adipose derived adult stem cells
R&D and non-clinical development
Clinical development MA Applic.
Marketing Authorization
In VivoTesting
Biomaterial R&D
In vitro testing
GMP grade
Phase I
Phase II
Phase III
2007-20102007-2010 2010-20182010-2018 20192019 20202020
Phase IV
Stemmatters Life BankingStem cell isolation and storage services
Stemmatters BiomedicalProducts and services for R&D
StemmattersTherapeutics
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Rui A. SousaCEO
Tel. +351-253-540100Fax. +351-253-540199
E-mail: [email protected]
ContactsContacts
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Life BankingStemmatters Life Banking
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Current MarketsCurrent Markets
Main application markets for stem cells
Current uses of stem cells are made in 3 distinct medical related markets:
Cell banking;
Therapeutic development;
Cell therapies.
(source: Frost & Sullivan).
StemmattersLife Banking
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Current OfferingCurrent Offering
Stemmatters Life Banking | Stem cell isolation and storage services
Bone marrow (onstem service – B2C); Adipose tissue (adstem service – B2C):
The treatment of tissues and biological residues generated in surgical procedures assures a cell banking opportunity not yet addressed.
Market potential for the isolation and storage of adipose derived adult stem cells for autologous application is estimated to worth:
• 75 million €/year for Spain, France, Germany, UK, Italy and Portugal;
• 120 million €/year for EU15.
Assures a polyvalent platform for regenerative technologies; Assures positive cash flow and supports leveraging of R&D pipeline.
StemmattersLife Banking
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Life Banking | Stem cell isolation and storage services
CompetitionCompetition StemmattersLife Banking
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Current OfferingCurrent Offering
Stemmatters Life Banking | Stem cell isolation and storage services
Acquisition Drivers Increased value of the surgical procedure; Potential application in future autologous regenerative therapies; Allows for off the shelf availability of personalized regenerative products; Decreases time for clinical delivery of therapy.
Current applications of adipose derived adult stem cells Radiation Necrosis
Breast Reconstruction
Heart Attack
Chronic Heart Disease
Crohn’s Disease
Tracheal Fistula Healing
Calvarial Repair
Marrow Transplant Complications
Diabetes
StemmattersLife Banking
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters BiomedicalStemmatters Biomedical
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Stemmatters Biomedical | Products and services for R&D
Current OfferingCurrent Offering
Isolation and processing services of human cells: Human stromal vascular fraction isolated from adipose tissue
containing human adipose derived stem cells (all samples are characterized for cell number and viability);
Human adipose derived stem cells (all samples are characterized for cell number and viability, as well as multipotent mesenchymal stem cell markers: CD29, CD105, CD34 and CD45);
• Pre-clinical research in regenerative medicine accounts for a market volume of about 700 million €/year.
Cell culturing products; Hydrogel support systems for 3D cell culturing;
• Very high R&D visibility among the potential buyer community;
• The global market potential for the commercialization of 3D supports for non-clinical R&D is estimated to worth between 7 and 35 million €/year.
Device for dynamic cell seeding and culturing.
StemmattersBiomedical
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Corporate StrategyCorporate Strategy
R&D Stemmatters Therapeutics
Stemmatters Biomedical
Stemmatters Life Banking
Trade sale
Licensing
Spin-off
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Corporate StrategyCorporate Strategy
R&D
Time to Market
Time inCorporate
Portfolio
Stemmatters Biomedical
Stemmatters Life Banking
Stemmatters Therapeutics
Technology
OtherCompany
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Financial projectionsFinancial projections
Stemmatters, Biotecnologia e Medicina Regenerativa LdaAVEPARK - Parque de Ciência e Tecnologia S.A.
Zona Industrial da Gandra | S. Cláudio do BarcoAPARTADO 4152 | 4805 CALDAS DAS TAIPAS
E-mail: [email protected]: www.stemmatters.com
Financial ProjectionsFinancial Projections
2009-2016